Anti-relapse prophylactic activity of inoculating Natural Killer (NK) cells as consolidation therapy of acute myeloid leukemia in pediatric patients with cytologic remission. The patients included have intermediate risk of relapse and no indication for allogeneic hematopoietic stem cell transplantation. After the standard induction and consolidation chemotherapy treatment, patients will receive five days of fludarabine. Two different NK cells infusions will be performed within one week (day 0 and 7), with Interleukin 2 (IL-2) infusion. Here, IL2 is linked to acute myeloid leukemia.